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A BS T R AC T
BACKGROUND

Randomized trials have shown that the transplantation of filgrastim-mobilized
peripheral-blood stem cells from HLA-identical siblings accelerates engraftment but
increases the risks of acute and chronic graft-versus-host disease (GVHD), as compared with the transplantation of bone marrow. Some studies have also shown that
peripheral-blood stem cells are associated with a decreased rate of relapse and improved survival among recipients with high-risk leukemia.
METHODS

We conducted a phase 3, multicenter, randomized trial of transplantation of peripheral-blood stem cells versus bone marrow from unrelated donors to compare 2-year
survival probabilities with the use of an intention-to-treat analysis. Between March
2004 and September 2009, we enrolled 551 patients at 48 centers. Patients were
randomly assigned in a 1:1 ratio to peripheral-blood stem-cell or bone marrow transplantation, stratified according to transplantation center and disease risk. The median follow-up of surviving patients was 36 months (interquartile range, 30 to 37).
RESULTS

The overall survival rate at 2 years in the peripheral-blood group was 51% (95%
confidence interval [CI], 45 to 57), as compared with 46% (95% CI, 40 to 52) in the
bone marrow group (P = 0.29), with an absolute difference of 5 percentage points
(95% CI, −3 to 14). The overall incidence of graft failure in the peripheral-blood group
was 3% (95% CI, 1 to 5), versus 9% (95% CI, 6 to 13) in the bone marrow group
(P = 0.002). The incidence of chronic GVHD at 2 years in the peripheral-blood group
was 53% (95% CI, 45 to 61), as compared with 41% (95% CI, 34 to 48) in the bone
marrow group (P = 0.01). There were no significant between-group differences in the
incidence of acute GVHD or relapse.
CONCLUSIONS

We did not detect significant survival differences between peripheral-blood stem-cell
and bone marrow transplantation from unrelated donors. Exploratory analyses of
secondary end points indicated that peripheral-blood stem cells may reduce the risk
of graft failure, whereas bone marrow may reduce the risk of chronic GVHD.
(Funded by the National Heart, Lung, and Blood Institute–National Cancer Institute
and others; ClinicalTrials.gov number, NCT00075816.)
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I

n the early days of allogeneic hematopoietic stem-cell transplantation, the only
graft source available was bone marrow harvested from the pelvis of a donor under anesthesia. When studies showed that an increased dose
of bone marrow cells correlated with more robust
hematopoietic engraftment and lower mortality
from infectious complications, transplantation
centers began to use filgrastim-stimulated peripheral blood, which has a much higher content
of blood progenitor cells than bone marrow, although there was concern that the higher T-cell
content might increase the risk of graft-versushost disease (GVHD).1-5 Several large, randomized trials of transplantation between HLA-identical siblings showed that peripheral-blood stem
cells resulted in better engraftment but increased
the risk of acute and chronic GVHD.4-11 Some
studies showed a decreased rate of relapse and
better survival with peripheral-blood stem cells, as
compared with bone marrow, especially among
patients with high-risk blood-cell cancers. However, the results obtained with transplants from
HLA-identical siblings may not be applicable to
transplants from unrelated donors, given the
greater genetic diversity and, therefore, greater
risk of GVHD in the unrelated recipient, even if
the donor and recipient are fully HLA-matched.
Over the past decade, the use of peripheralblood stem cells has increased and now accounts
for 75% of stem-cell transplants from unrelated
adult donors, without clinical data to support this
shift.12 A large observational study of unrelateddonor transplants showed higher rates of acute
and chronic GVHD with peripheral-blood stem
cells than with bone marrow and no improvement in survival.13 To determine the effects
of graft source for unrelated-donor transplants,
we performed a randomized trial comparing outcomes of peripheral-blood stem-cell and bone
marrow transplantations.

ME THODS
STUDY DESIGN

The study was an open-label, phase 3, multicenter,
randomized trial conducted by the Blood and
Marrow Transplant Clinical Trials Network. Randomization was performed in a 1:1 ratio, with the
use of random block sizes, and was stratified according to transplantation center and disease risk.
The target enrollment was 550 donor–recipient
pairs. The primary end point was 2-year survival
1488
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as assessed by means of an intention-to-treat analysis. Prespecified secondary end points included
post-transplantation incidences of neutrophil and
platelet engraftment, graft failure, acute and chronic GVHD, relapse, and infections. Other end points
included adverse events, immune reconstitution,
time to discontinuation of immunosuppressive
therapy, and quality of life. This article focuses on
the primary end point and clinical secondary end
points. Analyses of immune reconstitution and
quality of life are ongoing.
Enrollment began on March 31, 2004, and
ended on September 9, 2009. The analysis included
data collected as of November 15, 2011. The median follow-up of surviving patients is 36 months
(interquartile range, 30 to 37). Patients were followed in the study for 3 years, with a late analysis at 5 years planned with the use of data from
the Center for International Blood and Marrow
Transplant Research, which tracks the outcomes
of all allogeneic transplantations in the United
States.
PATIENTS

Eligible patients were less than 66 years of age and
were planning to undergo transplantation for acute
leukemia, myelodysplasia, chronic myeloid or
myelomonocytic leukemia, or myelofibrosis.
These diseases accounted for approximately 75%
of unrelated-donor transplantations in the United States during the study period. Exclusion criteria were donor-specific anti-HLA antibodies,
prior allogeneic or autologous transplantation,
human immunodeficiency virus infection, pregnancy or breast-feeding, cardiac insufficiency or
coronary artery disease requiring treatment, active infection, or concomitant enrollment in a
phase 1 study. Additional exclusion criteria were a
serum level of creatinine, bilirubin, alanine aminotransferase, or aspartate aminotransferase that
was greater than two times the upper limit of the
normal range, as well as a forced vital capacity,
forced expiratory volume in 1 second, or diffusing capacity of the lung for carbon monoxide that
was less than 50% of the predicted value.
TREATMENT

The protocol required DNA typing of the patient
and donor at intermediate resolution for HLA-A,
B, and C and at high resolution for DRB1, as well
as matching for five or six of the six HLA-A, B,
and DRB1 antigens. All donors and recipients gave
written informed consent before enrollment. Bone
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marrow cells were collected from the donors by
means of standard procedures. Peripheral-blood
stem-cell donors were prescribed filgrastim (at the
North American centers) or lenograstim (at the
German centers) at a dose of 10 μg per kilogram
of body weight per day for 5 days and underwent
a single large-volume apheresis on day 5 or two
smaller-volume apheresis procedures on days 5 and
6. Bone marrow or peripheral-blood stem cells
were not T-cell–depleted or cryopreserved before
transplantation. No blinding was attempted.
Patients received one of four conditioning regimens (cyclophosphamide and total-body irradiation; cyclophosphamide and busulfan; fludarabine,
busulfan, and antithymocyte globulin; or fludarabine and melphalan), with the minimum dose of
each agent defined in the protocol (Table 1). The
cyclophosphamide-containing regimens are myeloablative, whereas the fludarabine-containing
regimens are reduced-intensity conditioning regimens. Patients received one of two GVHD-prophylaxis regimens (tacrolimus and methotrexate, or
cyclosporine and methotrexate), with or without
additional agents. Both the conditioning and
GVHD-prophylaxis regimens had to be specified
before randomization. Supportive care and treatment for GVHD were provided according to institutional standards. A committee of investigators
who were unaware of the study assignments reviewed all case records, focusing on causes of
death, relapse, acute and chronic GVHD, and graft
failure. The protocol is available with the full text
of this article at NEJM.org and on a public website (www.bmtctn.net).
A protocol review committee appointed by the
National Heart, Lung, and Blood Institute approved the research protocol, which was also approved by local institutional review boards and
ethics committees. All authors vouch for the accuracy and completeness of the reported data and
analyses and for the adherence of the study to the
protocol. The data and safety monitoring board
appointed by the National Heart, Lung, and Blood
Institute also reviewed the analyses.
STATISTICAL ANALYSIS

After accounting for an anticipated 5% of patients
not undergoing transplantation, we calculated
that the study would have 80% power to detect a
difference of 12.5 percentage points in the 2-year
survival rate between the two study groups (35.0%
and 47.5%), with the use of a chi-square test and
a two-sided alpha level of 5%. There was no pren engl j med 367;16

defined anticipated direction of the survival difference between the two treatment groups. All
patients who underwent randomization were included in the primary, intention-to-treat analysis
of overall survival. Survival times were calculated
from the date of randomization.
The primary analysis was planned as a pointwise comparison of overall survival at 2 years
rather than as a log-rank test because of concerns
about nonproportional hazards between the two
groups. However, the final analyses did not show
violations of hazard proportionality, and therefore,
results of the Cox model are also presented. The
primary comparison of 2-year survival was performed with the use of a stratified binomial comparison (Mantel–Haenszel test), stratified according to transplantation center and disease risk.
Kaplan–Meier survival curves were constructed
for each group.
For analyses of the secondary end points, data
on transplantation-related events were collected
only for patients who underwent transplantation,
and event times were calculated from the date of
transplantation. There was no explicit adjustment
for multiple testing of secondary end points, and
since the primary statistical hypothesis was not
rejected, all the secondary analyses are considered
exploratory. Results are presented according to
study group. The rates of neutrophil and platelet
engraftment, graft failure, acute GVHD, chronic
GVHD, death in the absence of relapse, and relapse were compared between the two groups with
the use of a stratified log-rank test that treated
relapse as a competing event for death in the absence of relapse and treated death as a competing
risk for all other end points. Cumulative incidence
curves were estimated for each group.14 Chronic
GVHD was classified as limited or extensive, as
previously reported,15 because the study protocol
was written before the National Institutes of
Health workshop that redefined diagnostic and
staging criteria for chronic GVHD.16
However, chronic GVHD did not include cases
with sole manifestations of late acute GVHD that
occurred more than 100 days after transplantation. Inclusion of these late cases in the analyses
of acute GVHD did not change the results (data
not shown). The probabilities of being alive and
free of immunosuppressive treatment at 2 years
were compared between the two study groups
with the use of the chi-square test. Two-year rates
of overall survival and disease-free survival since
transplantation were compared between patients
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according to their randomly assigned treatment
group with the use of a stratified Mantel–
Haenszel test. In addition, a planned secondary
analysis of outcomes was conducted with the use
of Cox regression to adjust for the characteristics
of the patients.
Covariates considered in the model-building
process were transplantation center, year of transplantation, conditioning regimen, GVHD prophylaxis, recipient characteristics (age, sex, race,
Karnofsky performance-status score [with scores
ranging from 0 to 100 and higher scores indicat-
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ing better performance status], diagnosis, disease
stage, time from diagnosis to transplantation, status with respect to cytomegalovirus [CMV] serologic testing and coexisting diseases), donor characteristics (age, sex, race, status with respect to
CMV infection, and parity), and HLA matching.
Post hoc HLA typing included high-resolution
testing for HLA-A, B, C, and DRB1, and the degree
of donor–recipient mismatching was defined with
the use of these alleles, on the basis of work by
Lee et al.17 Preplanned subgroup analyses of survival according to age, HLA matching, and disease

Table 1. Characteristics of the Patients, Donors, and Transplantation Regimens, According to Study Group.*
Bone Marrow
(N = 278)

Peripheral-Blood
Stem Cells
(N = 273)

130 (47)

131 (48)

First complete remission

61 (22)

60 (22)

Second complete remission

32 (12)

32 (12)

Characteristic
Diagnosis — no. (%)
Acute myeloid leukemia

Third or subsequent complete remission

5 (2)

3 (1)

32 (12)

36 (13)

61 (22)

56 (21)

First complete remission

21 (8)

30 (11)

Second complete remission

25 (9)

18 (7)

Relapse
Acute lymphoblastic leukemia

Third or subsequent complete remission

5 (2)

1 (0)

10 (4)

7 (3)

29 (10)

37 (14)

20 (7)

24 (9)

Accelerated phase

6 (2)

7 (3)

Blast phase

3 (1)

6 (2)

52 (19)

41 (15)

Refractory anemia, RARS, or RCMD

15 (5)

12 (4)

RAEB-1 or RAEB-2†

22 (8)

17 (6)

Other

15 (5)

12 (4)

Chronic myelomonocytic leukemia

4 (1)

4 (1)

Myelofibrosis

2 (1)

4 (1)

Relapse
Chronic myeloid leukemia
Chronic phase

Myelodysplastic syndrome

High-risk disease — no. (%)‡
Age >40 yr — no. (%)

78 (28)

77 (28)

159 (57)

159 (58)

Male sex — no. (%)

168 (60)

146 (53)

White race — no. (%)§

250 (90)

248 (91)

Karnofsky performance-status score ≥90% — no./total no. (%)¶

172/240 (72)

154/228 (68)

Seropositivity for cytomegalovirus — no./total no. (%)

142/263 (54)

123/261 (47)

Conditioning regimen — no. (%)
Cyclophosphamide and total-body irradiation‖

1490

133 (48)

133 (49)

Cyclophosphamide and busulfan**

90 (32)

75 (27)

Fludarabine, busulfan, and antithymocyte globulin††

39 (14)

40 (15)

Fludarabine and melphalan‡‡

16 (6)

25 (9)

n engl j med 367;16
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Table 1. (Continued.)

Characteristic

Bone Marrow
(N = 278)

Peripheral-Blood
Stem Cells
(N = 273)

67 (24)

59 (22)

183 (66)

196 (72)

28 (10)

18 (7)

GVHD prophylaxis — no. (%)
Cyclosporine and methotrexate
Tacrolimus and methotrexate
Other
Did not undergo transplantation — no. (%)
Antithymocyte globulin treatment — no./total no. (%)§§

14 (5)

11 (4)

65/258 (25)

72/255 (28)

No. of donor mismatches at HLA-A, B, C, and DRB1 — no./total no. (%)¶¶
0

200/264 (76)

209/262 (80)

1

55/264 (21)

50/262 (19)

2

7/264 (3)

3/262 (1)

3

2/264 (1)

0/262

CD34+ cell dose per kilogram (×10−6)‖‖
Median
Interquartile range

2.75

7.70

1.94–4.53

5.43–11.28

* The CD34+ cell counts differed significantly between the two groups (P<0.001). There were no other significant betweengroup differences. GVHD denotes graft-versus-host disease, RAEB refractory anemia with excess of blasts, RARS
refractory anemia with ring sideroblasts, and RCMD refractory cytopenia with multilineage dysplasia.
† RAEB-1 is characterized by 5 to 9% blasts in bone marrow, and RAEB-2 by 10 to 19% blasts in bone marrow.
‡ High-risk disease includes acute myeloid leukemia in third or subsequent remission or not in remission, acute lymphoblastic leukemia not in remission, the myelodysplastic syndrome with excess blasts in transformation, chronic myeloid
leukemia in blast phase, and chronic myelomonocytic leukemia in any stage.
§ Race was determined by the investigators.
¶ Scores on the Karnofsky performance-status scale range from 0 to 100, with higher scores indicating better performance
status.
‖ The required minimum doses for this conditioning regimen were cyclophosphamide at a dose of 120 mg per kilogram
of body weight and a fractionated total-body irradiation of 12 Gy.
** The required minimum doses for this conditioning regimen were cyclophosphamide at a dose of 120 mg per kilogram
given intravenously and busulfan at a dose of 14 mg per kilogram given orally or 11.2 mg per kilogram given intravenously or an average targeted serum concentration greater than 600 ng per milliliter.
†† The required minimum doses for this conditioning regimen were fludarabine at a dose of 120 mg per square meter of
body-surface area and busulfan at a dose of 8 mg per kilogram or 250 mg per square meter. The protocol did not
specify a minimum dose for antithymocyte globulin.
‡‡ The required minimum doses for this conditioning regimen were fludarabine at a dose of 120 mg per square meter
and melphalan at a dose of 140 mg per square meter.
§§ Data on treatment with antithymocyte globulin were not collected for patients who did not undergo transplantation. Data
were also missing for several patients who did undergo transplantation.
¶¶ Data on donor HLA mismatch were not collected for patients who did not undergo transplantation.
‖‖ Data on CD34+ cell dose were missing for 121 patients (44%) in the bone marrow group and 25 (9%) in the peripheralblood group.

risk were conducted with the use of an interaction test in the Cox proportional-hazards model.
The statistical analyses were performed with the
use of SAS software, version 9.2 (SAS Institute).

groups were well balanced with respect to age,
sex, Karnofsky performance-status score, diagnosis, disease risk, positive result on serologic
testing for CMV, and race. Patients were treated in
48 transplantation centers in the United States and
Canada. Donors were from 54 National Marrow
R E SULT S
Donor Program–affiliated donor centers in the
CHARACTERISTICS OF THE PATIENTS AND DONORS
United States, Canada, and Germany. The proporThe characteristics of the patients and donors are tion of donors who were fully matched for HLAshown in Table 1, along with details of the treat- A, B, C, and DRB1 and other donor characterisments. The bone marrow and peripheral-blood tics were similar between the two study groups.
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Figure 2 (facing page). Outcomes after Transplantation,
According to Study Group.
Panel A shows the rate of overall survival, and Panel B
the rate of disease-free survival. Panel C shows the incidence of death unrelated to relapse. Panel D shows
the incidence of relapse. Panel E shows the incidence
of neutrophil engraftment (>500 neutrophils per cubic
millimeter), and Panel F the incidence of platelet engraftment (>20,000 platelets per cubic millimeter, without
platelet transfusion during the prior 7 days). Panel G
shows the incidence of acute graft-versus-host disease
(GVHD) of grades II to IV, and Panel H the incidence
of chronic GVHD. P values for the between-group differences in overall survival (Panel A) and disease-free survival (Panel B) are from a stratified binomial comparison
at the 2-year point; P values from stratified log-rank
tests for survival and disease-free survival were also
not significant. All other P values shown are from
stratified log-rank tests.

100

60

of

3

Years since Randomization

Figure 1. Survival after Randomization in the Intention-to-Treat Analysis.
The P value is from a stratified binomial comparison at the 2-year point. The
P value from a stratified log-rank test was also not significant. A total of 75 patients in each group were still alive at 36 months.

SURVIVAL AND RELAPSE AFTER TRANSPLANTATION
TREATMENT COMPLIANCE

More than 90% of the patients received a transplant from the assigned graft source. Five percent
of the patients randomly assigned to the bone
marrow group and 4% of those randomly assigned
to the peripheral-blood group did not undergo
transplantation but were included in the intentionto-treat analysis. The primary reason for not undergoing transplantation (accounting for 84% of
these patients) was relapse of cancer. Twelve patients (4%) randomly assigned to the bone marrow
group received peripheral-blood stem cells owing
to concern that a bone marrow harvest would delay the transplantation (six patients) or because of
a preference of the donor (four) or physician (two).
One patient (<1%) randomly assigned to the peripheral-blood group received bone marrow because of donor preference. Overall, 98% of the
patients received the conditioning regimen and
GVHD prophylaxis chosen before randomization
by the physician in charge of the transplantation.
INTENTION-TO-TREAT ANALYSIS

The primary end point was the overall survival
rate at 2 years according to an intention-to-treat
analysis. The 2-year overall survival rate in the
peripheral-blood group was 51% (95% confidence
interval [CI], 45 to 57), as compared with 46%
(95% CI, 40 to 52) in the bone marrow group
(stratified odds ratio, 1.20; 95% CI, 0.85 to 1.70;
P = 0.29) (Fig. 1). The absolute difference in overall survival at 2 years was 5 percentage points
(95% CI, −3 to 14).
1492
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The following analyses were restricted to patients
who received the transplant. The rate of overall survival at 2 years after transplantation did not differ
significantly in pointwise comparisons between
the group randomly assigned to receive peripheral
blood and the group assigned to receive bone marrow (estimated difference of 4 percentage points;
95% CI, −4 to 13; P = 0.33) (Fig. 2A); neither did
the rate of disease-free survival at 2 years (estimated difference of 3 percentage points; 95% CI,
−5 to 12; P = 0.38) (Fig. 2B). Mortality unrelated to
relapse was similar at 2 years in the two treatment groups (estimated difference of 2 percentage
points; 95% CI, −6 to 9; P = 0.66) (Fig. 2C), as was
the rate of relapse (estimated difference of 1 percentage point; 95% CI, −7 to 9; P = 0.74) (Fig. 2D).
A sensitivity analysis that was performed with the
use of multivariate Cox models with adjustment for
age, disease risk, HLA matching, status with regard
to the diffusing capacity of the lung for carbon
monoxide, and conditioning regimen also showed
similar results for overall survival and disease-free
survival (P = 0.70 and P = 0.71, respectively). As expected, younger recipient age, low disease risk, and
HLA matching of the donor (eight of the eight HLA
alleles vs. seven of the eight) were associated with
increased survival, but these variables had no interaction with stem-cell source (data not shown).
REPORTED ADVERSE EVENTS

The frequency of reported adverse events did not
differ significantly between the two groups (Table
S1 in the Supplementary Appendix, available at
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NEJM.org). The median duration of the first hospitalization for the transplantation was 5 days
shorter among patients who received peripheralblood stem cells than among those who received
bone marrow (P<0.001), but the median number
of days that transplant recipients were hospitalized during the first year of the study was similar
in the two groups (37 days in each group, P = 0.41).

more common in the peripheral-blood group,
whereas deaths attributed to graft failure were
more common in the bone marrow group (P = 0.002)
(Table 2). Acute and chronic GVHD were the predominant causes of deaths unrelated to relapse in
both groups.

ENGRAFTMENT

This large, multicenter, randomized trial did not
show a significant survival difference between
transplant recipients who received peripheralblood stem cells and those who received bone
marrow from unrelated donors. Results were
similar among HLA-mismatched pairs, recipients with advanced disease, and recipients older
than 40 years of age, although this trial was not
powered to detect potential differences within
these subsets. Other transplantation outcomes,
including relapse rates, mortality unrelated to relapse, and rates of acute GVHD, were also similar
with the two types of grafts, except that peripheral-blood stem-cell transplants were associated
with better engraftment and bone marrow transplants with less extensive chronic GVHD.
Our study was not powered to support firm
conclusions on several issues of interest. However, it
is possible to make some testable inferences from
our results. These results show that although the
two graft sources are associated with similar survival rates after transplantation, specific characteristics of the patients may suggest the preferential
use of peripheral-blood stem cells or bone marrow.
Peripheral-blood stem cells may be recommended
for patients at higher risk for graft failure.18-20
For example, patients with malignant diseases
who have never undergone cytotoxic chemotherapy may be at increased risk for rejection of a bone
marrow graft and might benefit from peripheralblood stem cells.21 Bone marrow may be recommended for all other patients, especially those
who are immunosuppressed owing to prior chemotherapy, since they have a lower risk of graft
rejection. For all patients, the use of bone marrow will decrease the risk of chronic GVHD.
Donor preference may also affect the choice of
stem-cell source. In our trial, 30% of screened
donors declined to undergo randomization, preferring one donation source over the other. Donors who participated in the trial and were randomly assigned to donate bone marrow reported
more discomfort early after the donation, but

Among patients randomly assigned to receive
peripheral-blood stem cells, as compared with
those randomly assigned to receive bone marrow,
the median time to neutrophil engraftment was
5 days shorter (P<0.001), and the median time to
platelet engraftment was 7 days shorter (P<0.001)
(Fig. 2E and 2F). Primary graft failure occurred in
2% of the patients randomly assigned to receive
peripheral-blood stem cells and in 6% of those
randomly assigned to receive bone marrow; secondary graft failure occurred in 1% and 3% of
patients, respectively. The total incidence of graft
failure was 3% (95% CI, 1 to 5) in the peripheralblood group and 9% (95% CI, 6 to 13) in the bone
marrow group (P = 0.002). The between-group difference in the incidence of all graft failures was
7 percentage points (95% CI, 2 to 11; P = 0.002).
ACUTE AND CHRONIC GVHD

The rate of acute GVHD of grades II to IV (Fig.
2G) and the rate of grade III or IV disease (data
not shown) were similar in the two groups. The
incidence of chronic GVHD at 2 years was significantly higher in the peripheral-blood group
than in the bone marrow group (53% [95% CI, 45
to 61] vs. 41% [95% CI, 34 to 48], P = 0.01 by the
stratified log-rank test) (Fig. 2H). The difference
in the incidence of chronic GVHD at 2 years was
12 percentage points (95% CI, 2 to 22). The proportion of patients with extensive chronic GVHD
was higher in the peripheral-blood group than in
the bone marrow group (48% [95% CI, 42 to 54]
vs. 32% [95% CI, 26 to 38], P<0.001). Among patients who were alive at 2 years, 57% of the patients in the peripheral-blood group were receiving immunosuppressive therapy, as compared with
37% of those in the bone marrow group (P = 0.03).
CAUSES OF DEATH

There was no significant between-group difference in the proportion of deaths from infection or
relapse. Deaths attributed to chronic GVHD were
1494
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symptoms at 8 weeks were similar to those in
the peripheral-blood stem-cell donors.22 The acquisition costs are similar for peripheral-blood
stem cells and bone marrow, according to the
National Marrow Donor Program fee schedule,
and therefore, graft-acquisition costs should not
affect the choice of stem-cell source.12
The present study included patients with leukemia or chronic myeloid disorders, 78% of whom
were treated with myeloablative conditioning regimens, and the results may not be generalizable to
other clinical situations. For example, reducedintensity regimens, including very-low-dose, nonmyeloablative conditioning regimens, are now
commonly used in patients older than 50 years
of age and in those with serious coexisting diseases.23 We did not find significant interactions
between graft sources and the intensity of the
conditioning regimen, but the range of intensity
was narrow. Nonmyeloablative regimens were
not allowed, and only 22% of the patients underwent a reduced-intensity regimen. Nonmyeloablative and reduced-intensity conditioning regimens provide less intensive immunosuppression,
and the stronger engraftment potential associated
with peripheral-blood stem-cell transplantation
could be advantageous in this situation.
Our results differ somewhat from the findings
in studies of transplantation from HLA-identical
siblings. In some of these studies, the use of
peripheral-blood stem cells improved survival
among patients with advanced disease, predominantly by decreasing the risk of relapse.24,25 This
discrepancy may be due to differences in the study
populations. Chronic myeloid leukemia is the disease most sensitive to the antileukemia effect of
peripheral-blood stem-cell transplantation from
siblings. Patients with chronic myeloid leukemia
accounted for only 12% of our study population,
as compared with 40 to 50% of patients in the
sibling trials, probably because imatinib and
other similar drugs had been approved for use in
the interim.24-26 It is also possible that increased
mortality from chronic GVHD among recipients
of peripheral-blood stem cells from unrelated
donors offsets the benefits associated with the
more rapid and robust engraftment that occurs
with peripheral-blood stem cells, as compared
with bone marrow.27,28 Given the greater genetic
disparity between unrelated donors and recipients, current regimens for GVHD prophylaxis
may not adequately counteract the increased risk
n engl j med 367;16

Table 2. Primary Causes of Death among Patients Who
Underwent Transplantation.*

Cause of Death

Bone Marrow
(N = 145)

Peripheral-Blood
Stem Cells
(N = 145)

number (percent)
Relapse

73 (50)

69 (48)

Infection

13 (9)

8 (6)

Graft failure

11 (8)

Acute GVHD

20 (14)

24 (17)

0

Chronic GVHD

14 (10)

30 (21)

Other

14 (10)

14 (10)

* P = 0.002 for the overall comparison between the groups.
Percentages do not add up to 100 because of rounding.

of GVHD that is associated with the higher numbers of T cells in peripheral-blood stem cells.
In conclusion, the rates of survival, relapse,
and acute GVHD are similar with bone marrow
and peripheral-blood stem-cell grafts from unrelated donors, but engraftment is better with peripheral-blood stem cells and the rate of chronic
GVHD is lower with bone marrow. In addition
to the relevance of these findings to the selection of a graft source for transplantation from
unrelated donors, our results suggest that there
is a need to develop transplantation approaches
that decrease the risk of graft failure when bone
marrow is used and that decrease the risks of
acute and extensive chronic GVHD when either
stem-cell source is used. Antilymphocyte globulin has shown promise in preventing moderateto-severe chronic GVHD after transplantation
from an unrelated donor.29,30 Alternatively, hematopoietic cells collected from bone marrow
after donor treatment with growth factors may
facilitate engraftment without increasing the risk
of GVHD.9 Prospective randomized clinical trials
are comparing this stem-cell source with unstimulated bone marrow or mobilized peripheralblood stem cells in recipients of transplants from
HLA-identical siblings.
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